Bevacizumab — knowledge graph · CancerIndex

Knowledge graph · Drug

Bevacizumab

monoclonal antibody

Identifier: CI-DRUG-00000107
Entity page: /drug/bevacizumab ↗
Edges: 2,512

Neighbours: 202 cancers1 genes11 variants10 trials15 approvals
Drawn: 60 of 239 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Bevacizumab approved for …APPROVED_FOR30 of 43show all (up to 200)
→ approved for	Hepatocellular Carcinomasubtype	supports	FDA ORIG	Hepatocellular Carcinoma	1	Regulatory	openfda	graph →
→ approved for	Malignant Peritoneal Neoplasmsubtype

→ approved for

EMA · EU · 2022VEGZELMA in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. VEGZELMA in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. VEGZELMA in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with VEGZELMA in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. VEGZELMA, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (NSCLC) other than predominantly squamous cell histology. VEGZELMA, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent NSCLC with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). VEGZELMA, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. VEGZELMA, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). VEGZELMA, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor–targeted agents. VEGZELMA in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1). VEGZELMA, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

EMA (EU) · approved · 2022-08-17 · VEGZELMA in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of …

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1). Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

EMA (EU) · approved · 2021-04-21 · Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of th…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. Alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Alymsys in combination with capecitabine. Alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. Alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · approved · 2021-03-26 · Alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of t…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Oyavas in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. Oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1). Oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents. Oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents (see Section 5.1). Oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

EMA (EU) · approved · 2021-03-26 · Oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of th…

—

approved

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2021Onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Onbevzi in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. Onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor targeted agents. Onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · withdrawn · 2021-01-11 · Onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of t…

—

withdrawn

not mapped

Regulatory

ema

open ↗

→ approved for

EMA · EU · 2020Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Bevacizumab in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1. Bevacizumab in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Equidacent in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1. Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations. Bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer. Bevacizumab, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1). Bevacizumab, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents. Bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

EMA (EU) · withdrawn · 2020-09-24 · Bevacizumab in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma …

—

withdrawn

not mapped

Regulatory

ema

open ↗

Bevacizumab predicts response to …PREDICTS_RESPONSE_TO12 of 12
← predicts response to	MMP2 SERUM LEVELS 2 source records aggregated	sensitivity	B	Breast Inflammatory Carcinoma	2	Curated	civic	graph →
← predicts response to	PPP1R15A RS557806SNV	sensitivity	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	IDH1 R132	sensitivity	B	High-Grade Glioma, NOS	1	Curated	civic	graph →
← predicts response to	EPHB4 EXPRESSIONexpression	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	EGFR Exon 18 Overexpressionexpression	sensitivity	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
← predicts response to	VEGFA Decreased Peri-therapeutic Expressionexpression	sensitivity	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	BRAF Mutationother	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	BRAF V600ESNV	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	MMP9 SERUM LEVELS	resistance	B	Breast Inflammatory Carcinoma	1	Curated	civic	graph →
← predicts response to	KRAS Mutationother	resistance	B	Malignant Colorectal Neoplasm	1	Curated	civic	graph →
← predicts response to	BRAF Fusionfusion 2 source records aggregated	sensitivity	C	Spindle Cell Sarcoma	2	Curated	civic	graph →
← predicts response to	BRAF V600ESNV	sensitivity	D	Malignant Colorectal Neoplasm	1	Curated	civic	graph →

Bevacizumab targets …TARGETS1 of 1
→ targets	VEGFA	—	INHIBITOR	—	1	Curated	chembl	graph →

Bevacizumab investigated for …INVESTIGATED_FOR15 of 109show all (up to 200)
→ investigated for	Malignant Colorectal Neoplasmsubtype 6 source records aggregated	supports	B	Malignant Colorectal Neoplasm	6	Curated	civic	graph →
→ investigated for	Breast Inflammatory Carcinomasubtype 2 source records aggregated	supports	B	Breast Inflammatory Carcinoma	2	Curated	civic	graph →
→ investigated for	High-Grade Glioma, NOSsubtype	supports	B	High-Grade Glioma, NOS	1	Curated	civic	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	supports	B	Lung Non-Small Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Fallopian Tube Neoplasmsubtype	unknown	4	Fallopian Tube Neoplasm	1	Curated	chembl	graph →
→ investigated for	Colon Neoplasmsubtype	unknown	4	Colon Neoplasm	1	Curated	chembl	graph →
→ investigated for	Peritoneal Neoplasmcancer_family	unknown	4	Peritoneal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Cervical Neoplasmsubtype	unknown	4	Cervical Neoplasm	1	Curated	chembl	graph →
→ investigated for	Ovarian Neoplasmsubtype	unknown	4	Ovarian Neoplasm	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Renal Cell Carcinomasubtype	unknown	4	Renal Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Lung Non-Small Cell Carcinomasubtype	unknown	4	Lung Non-Small Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Glioblastomasubtype	unknown	4	Glioblastoma	1	Curated	chembl	graph →
→ investigated for	Colorectal Neoplasmsubtype	unknown	4	Colorectal Neoplasm	1	Curated	chembl	graph →
→ investigated for	Breast Neoplasmcancer_family	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →

Bevacizumab investigated in trials for …INVESTIGATED_IN_TRIALSderived200 of 526show all (up to 200)
→ investigated in trials for	Malignant Colorectal Neoplasmsubtype 315 trials (89 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	315	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 146 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	146	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasmcancer_family 144 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	144	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Neoplasm 110 trials (46 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Neoplasm	110	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioblastomasubtype 107 trials (18 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioblastoma	107	Observed	clinicaltrials	graph →
→ investigated in trials for	Hepatocellular Carcinomasubtype 105 trials (62 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	105	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Neoplasmsubtype 63 trials (22 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Neoplasm	63	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Fallopian Tube Neoplasm 61 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Fallopian Tube Neoplasm	61	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 61 trials (35 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	61	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 57 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 57 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	57	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Cell Carcinomasubtype 52 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Cell Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Carcinoma 47 trials (14 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Carcinoma	47	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Pancreatic Neoplasm 46 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Pancreatic Neoplasm	46	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Rectal Neoplasm 45 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Rectal Neoplasm	45	Observed	clinicaltrials	graph →
→ investigated in trials for	Melanoma 35 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Melanoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colon Neoplasmcancer 31 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colon Neoplasm	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Cervical Neoplasmcancer 30 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Cervical Neoplasm	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal Carcinoma 29 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal Carcinoma	29	Observed	clinicaltrials	graph →
→ investigated in trials for	Neoplasmcancer_family 28 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neoplasm	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Squamous Non-Small Cell Carcinomasubtype 27 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Squamous Non-Small Cell Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Neoplasmsubtype 25 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Neoplasm	25	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Neoplasm 24 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Neoplasm	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Carcinoma 23 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Carcinoma	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Liver Neoplasm 22 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Liver Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Neoplasmcancer_family 21 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Neoplasm	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Glioma 21 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Glioma	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Colorectal Adenocarcinoma 20 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colorectal Adenocarcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Gliosarcoma 20 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gliosarcoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Endometrioid Adenocarcinoma 20 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Endometrioid Adenocarcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Triple-Negative Breast Carcinoma 20 trials (10 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Triple-Negative Breast Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Rectal Adenocarcinoma 19 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Rectal Adenocarcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Carcinoma 18 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Carcinoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Gastric Neoplasm 18 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Gastric Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 17 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Solid Neoplasm 17 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Solid Neoplasm	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Endometrioid Adenocarcinoma 15 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Endometrioid Adenocarcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Adenocarcinoma 15 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Adenocarcinoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Peritoneal Neoplasmsubtype 15 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Peritoneal Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 15 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Endometrial Neoplasm 14 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Endometrial Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Kidney Neoplasm 14 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Kidney Neoplasm	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Clear Cell Adenocarcinoma 14 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Clear Cell Adenocarcinoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Undifferentiated Carcinoma 13 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Undifferentiated Carcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Platinum-Resistant Ovarian Carcinoma 13 trials (8 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Platinum-Resistant Ovarian Carcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Clear Cell Adenocarcinoma 12 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Small Cell Carcinoma 12 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Biliary Tract Neoplasm 12 trials (9 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Biliary Tract Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Serous Adenocarcinoma 12 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Serous Adenocarcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal Serous Adenocarcinoma 12 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal Serous Adenocarcinoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Brain Neoplasm 11 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Brain Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Neoplasmsubtype 11 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Undifferentiated Carcinoma 11 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Undifferentiated Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Esophageal Neoplasm 11 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Esophageal Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Pancreatic Adenocarcinoma 11 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pancreatic Adenocarcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Clear Cell Renal Cell Carcinoma 10 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Clear Cell Renal Cell Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Colon Adenocarcinoma 10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colon Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Mucinous Adenocarcinoma 10 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Mucinous Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Serous Adenocarcinoma 10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Serous Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Glioma 10 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Glioma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Seromucinous Carcinoma 10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Seromucinous Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Sarcoma 10 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Sarcoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Digestive System Neoplasm 9 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Digestive System Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Transitional Cell Carcinoma 9 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Transitional Cell Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinoma 9 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Carcinosarcoma 9 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Carcinosarcoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Mucinous Adenocarcinoma 9 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Mucinous Adenocarcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Transitional Cell Carcinoma 9 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Transitional Cell Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Glioblastoma 8 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Glioblastoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Carcinoma 8 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Carcinoma 8 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Colon Neoplasmsubtype 8 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Colon Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphoma 8 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Platinum-Sensitive Ovarian Carcinoma 8 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Platinum-Sensitive Ovarian Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal Clear Cell Adenocarcinoma 8 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal Clear Cell Adenocarcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Endometrial Carcinoma 7 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Endometrial Carcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Endometrial Serous Adenocarcinoma 7 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Endometrial Serous Adenocarcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Neoplasm 7 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Head and Neck Neoplasm 7 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Head and Neck Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal Endometrioid Adenocarcinoma 7 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal Endometrioid Adenocarcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Adenocarcinoma 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Astrocytoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Astrocytoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Cervical Squamous Cell Carcinoma 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cervical Squamous Cell Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemia 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Cutaneous Melanoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cutaneous Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Hypopharyngeal Squamous Cell Carcinoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hypopharyngeal Squamous Cell Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Laryngeal Squamous Cell Carcinoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Laryngeal Squamous Cell Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Large Cell Carcinoma 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Large Cell Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Digestive System Neoplasm 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Digestive System Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Multiple Myeloma 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Multiple Myeloma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian High Grade Serous Adenocarcinoma 6 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian High Grade Serous Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pancreatic Ductal Adenocarcinoma 6 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pancreatic Ductal Adenocarcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Peritoneal Neoplasmcancer_family 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Peritoneal Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Platinum-Resistant Fallopian Tube Carcinoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Platinum-Resistant Fallopian Tube Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Platinum-Resistant Primary Peritoneal Carcinoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Platinum-Resistant Primary Peritoneal Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal Undifferentiated Carcinoma 6 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal Undifferentiated Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Urothelial Carcinoma 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Urothelial Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Giant Cell Glioblastoma 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Giant Cell Glioblastoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Gliosarcoma 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Gliosarcoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cervical Adenocarcinoma 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cervical Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cervical Adenosquamous Carcinoma 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cervical Adenosquamous Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cervical Carcinomasubtype 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cervical Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Cholangiocarcinoma 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cholangiocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Diffuse Intrinsic Pontine Glioma 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Intrinsic Pontine Glioma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Endometrial Clear Cell Adenocarcinoma 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Endometrial Clear Cell Adenocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Squamous Cell Carcinoma 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Squamous Cell Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Uterine Corpus Neoplasm 5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Uterine Corpus Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Neuroendocrine Tumor 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neuroendocrine Tumor	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Oropharyngeal Squamous Cell Carcinoma 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Oropharyngeal Squamous Cell Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal Carcinosarcoma 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal Carcinosarcoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Rectal Neoplasm 5 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Rectal Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Anaplastic Astrocytoma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Anaplastic Astrocytoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Anaplastic Oligodendroglioma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Anaplastic Oligodendroglioma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Castration-Resistant Prostate Carcinoma 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Castration-Resistant Prostate Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Central Nervous System Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Central Nervous System Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Solid Neoplasm 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Solid Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Endometrial Neoplasm 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Endometrial Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube Adenocarcinoma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Fallopian Tube High Grade Serous Adenocarcinoma 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Fallopian Tube High Grade Serous Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastroesophageal Junction Adenocarcinoma 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastroesophageal Junction Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	High-Grade Serous Ovarian Cancer 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High-Grade Serous Ovarian Cancer	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Intestinal Neoplasm 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Intestinal Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Laryngeal Verrucous Carcinoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Laryngeal Verrucous Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemia 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Male Breast Carcinoma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Male Breast Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Bladder Neoplasm 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Brain Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Brain Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Mesothelioma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Mesothelioma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Myelodysplastic Syndrome 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myelodysplastic Syndrome	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Nasopharyngeal Undifferentiated Carcinoma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Nasopharyngeal Undifferentiated Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Neuroblastoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neuroblastoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphoma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Oral Cavity Verrucous Carcinoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Oral Cavity Verrucous Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Brenner Tumor 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Brenner Tumor	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Clear Cell Cystadenocarcinoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Clear Cell Cystadenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Mucinous Cystadenocarcinoma 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Mucinous Cystadenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Serous Cystadenocarcinoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Serous Cystadenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal High Grade Serous Adenocarcinoma 4 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal High Grade Serous Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Peritoneal Transitional Cell Carcinoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Peritoneal Transitional Cell Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Prostate Adenocarcinoma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Prostate Adenocarcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Soft Tissue Sarcoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Soft Tissue Sarcoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Uveal Melanoma 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Uveal Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Vestibular Schwannoma 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Vestibular Schwannoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Hepatocellular Carcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Hepatocellular Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Soft Tissue Sarcoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Soft Tissue Sarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Angiosarcoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Angiosarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Brain Stem Glioma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brain Stem Glioma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cervical Neoplasmsubtype 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Cervical Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Digestive System Neuroendocrine Tumor G1 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Digestive System Neuroendocrine Tumor G1	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Endometrial Adenocarcinoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Endometrial Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Endometrial Adenosquamous Carcinoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Endometrial Adenosquamous Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ependymoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ependymoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Gallbladder Adenocarcinoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gallbladder Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Giant Cell Glioblastoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Giant Cell Glioblastoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Hematopoietic and Lymphoid Cell Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hematopoietic and Lymphoid Cell Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	High-Grade Glioma, NOSsubtype 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High-Grade Glioma, NOS	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Kaposi Sarcoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Kaposi Sarcoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Kidney Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Kidney Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Lip Basal Cell Carcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lip Basal Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Liver Neoplasm 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Liver Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Female Reproductive System Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Female Reproductive System Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ovarian Brenner Tumor 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ovarian Brenner Tumor	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Salivary Gland Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Salivary Gland Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Medulloblastoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Medulloblastoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Meningeal Carcinomatosis 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Meningeal Carcinomatosis	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Merkel Cell Carcinoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Merkel Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Minimally Invasive Lung Adenocarcinoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Minimally Invasive Lung Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Nasopharyngeal Carcinoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Nasopharyngeal Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Neuroendocrine Carcinoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Neuroendocrine Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Oral Cavity Adenoid Cystic Carcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Oral Cavity Adenoid Cystic Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Oral Cavity Mucoepidermoid Carcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Oral Cavity Mucoepidermoid Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ovarian Adenocarcinoma 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ovarian Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pancreatic Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pancreatic Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Pancreatic Neuroendocrine Tumor 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Pancreatic Neuroendocrine Tumor	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Squamous Cell Carcinoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Squamous Cell Carcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemia 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Anaplastic Ependymoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Anaplastic Ependymoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Anaplastic (Malignant) Meningioma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Anaplastic (Malignant) Meningioma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Brain Glioblastoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Brain Glioblastoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Burkitt Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Burkitt Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Ependymoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Ependymoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Grade 2 Meningioma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Grade 2 Meningioma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Mixed Glioma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Mixed Glioma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Papillary Meningioma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Papillary Meningioma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Alveolar Soft Part Sarcoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Alveolar Soft Part Sarcoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Large Cell Lymphoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Large Cell Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Anaplastic Oligodendroglioma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Anaplastic Oligodendroglioma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Astrocytoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Astrocytoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Breast Adenocarcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Breast Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Brenner Tumor 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Brenner Tumor	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Cerebral Anaplastic Astrocytoma 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Cerebral Anaplastic Astrocytoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Malignant Neoplasm 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Malignant Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Medulloblastoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Medulloblastoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Spinal Cord Neoplasm 2 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Spinal Cord Neoplasm	2	Observed	clinicaltrials	graph →

Bevacizumab studied in …STUDIED_INderived10 of 1,821show all (up to 200)
→ studied in	NCT05007106Phase 2 · completed MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) · 1,821 trials list this drug (445 active)	—	—	Esophageal Neoplasm,Gastric Neoplasm,Gallbladder Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05482893Phase 1/Phase 2 · recruiting Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) · 1,821 trials list this drug (445 active)	—	—	Malignant Biliary Tract Neoplasm,Malignant Colorectal Neoplasm,Pancreatic Ductal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06820463Phase 2 · recruiting A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT06997497Phase 3 · recruiting A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) · 1,821 trials list this drug (445 active)	—	—	Colon Adenocarcinoma,Rectal Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07222800Phase 3 · recruiting Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active)	—	—	Neoplasm by Site,Digestive System Neoplasm,Intestinal Neoplasm+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT07346157Phase 1/Phase 2 · recruiting Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease · 1,821 trials list this drug (445 active)	—	—	Medulloblastoma,Childhood Medulloblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07446322Phase 2 · recruiting FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer · 1,821 trials list this drug (445 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07504588Phase 2 · recruiting Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy · 1,821 trials list this drug (445 active)	—	—	Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal Endometrioid Adenocarcinoma,Platinum-Sensitive Primary Peritoneal High Grade Serous Adenocarcinoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07525206Phase 3 · recruiting A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer · 1,821 trials list this drug (445 active)	—	—	Malignant Colorectal Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07756840Phase 2 · not yet recruiting Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) · 1,821 trials list this drug (445 active)	—	—	Respiratory System Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths